Before more evidence is available, dabigatran should be prescribed with caution in high-risk patients.

Retrospective analysis of Medicare data showed greater risk of bleeding than warfarin.

http://www.jwatch.org/fw109493/2014/11/04/dabigatran-linked-more-bleeding-events-warfarin-atrial#sthash.YNqT2DLh.dpuf